Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Retained Earnings (2016 - 2025)

Ani Pharmaceuticals' Retained Earnings history spans 16 years, with the latest figure at $1.0 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 80.67% year-over-year to $1.0 million; the TTM value through Dec 2025 reached $1.0 million, down 80.67%, while the annual FY2025 figure was $1.0 million, 80.67% down from the prior year.
  • Retained Earnings for Q4 2025 was $1.0 million at Ani Pharmaceuticals, down from $2.8 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $12.2 million in Q4 2022 and bottomed at -$96.3 million in Q1 2023.
  • The 5-year median for Retained Earnings is -$1.0 million (2021), against an average of -$24.9 million.
  • The largest annual shift saw Retained Earnings soared 498.3% in 2022 before it tumbled 3649.12% in 2023.
  • A 5-year view of Retained Earnings shows it stood at -$3.1 million in 2021, then skyrocketed by 498.3% to $12.2 million in 2022, then fell by 27.21% to $8.9 million in 2023, then plummeted by 39.66% to $5.3 million in 2024, then crashed by 80.67% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Retained Earnings are $1.0 million (Q4 2025), $2.8 million (Q3 2025), and -$76.9 million (Q2 2025).